Related Articles
Higher efficacy and complete response with administration of eribulin for recurrent squamous cell breast carcinoma: A case report
Efficacy, toxicity and prognostic factors of pyrotinib‑involved neoadjuvant therapy in HER2‑positive breast cancer: A retrospective study
Examination of the clinical usefulness of TS-1 in locally recurrent breast cancer
Selectively high efficacy of eribulin against high‑grade invasive recurrent and/or metastatic squamous cell carcinoma of the head and neck
Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature